A powerful cocktail of sedatives and antipsychotics similar to one involved in Risperdal lawsuit litigation is being doled out to thousands of nursing home residents in Ontario, and the results could be especially serious for patients with dementia, according to a report from the Star.com.

An article published April 21st relays the findings of a probe commissioned by the Health Ministry that looks into the widespread use of prescription medications in nursing home residents.  Among other things, the investigation reveals that more than a third of individuals in some 300 facilities are taking antipsychotics like Risperdal and Risperidone, as the drug is known in its generic form, to calm and “restrain” wandering and agitated behavior. These scripts are written to approximately 45 percent of all nursing home residents in Ontario between 65 and 79 years of age, the report states. Conversely, approximately 30 percent of patients between those ages are currently using sedatives such as diazepam and lorazepam.

Findings of this research, which showed a total of 10,220 seniors—equating to about 11 percent of all seniors in Ontario long-term care homes—taking both a sedative and antipsychotic, may be of particular interest to plaintiffs involved in Risperdal lawsuits.

Risperdal Lawsuit Claimants Reference $2.2 Billion Settlement over Drug

Hundreds of claims over the medication reference a recent settlement between Johnson & Johnson and the U.S. Department of Justice. The $2.2 billion agreement was reached in November 2013 and involved allegations from the federal government that the company promoted Risperdal for elderly patients with dementia and children, even though pediatric uses of the medication were not approved until 2006.  The findings of a federal probe into Johnson & Johnson’s marketing practices also led to allegations that the company failed to warn the general public about side effects that may be associated with the medication.

Many of the claims now pending in a consolidated litigation established in Pennsylvania state court allege that serious Risperdal gynecomastia complications may result from use of the medication, among other side effects. Male gynecomastia is a condition categorized by male breast growth, and has allegedly been experienced by several men and young boys involved in cases now consolidated in the Philadelphia Court of Common Pleas.

Start the Process of Filing a Risperdal Lawsuit

Contact our Firm today to learn more about Risperdal’s possible association with gynecomastia, and to find out if you are eligible to file a claim against its manufacturer. Call us now to learn more about your legal rights at (877) 779-1414.

Published April 24, 2014 by